Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment The patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor reduction maintained Consistently good safety and tolerability profile…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.